A Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

We worked with Axial and three other sites to assess the safety, tolerability and efficacy of a pharmaceutical therapy called AB-2004.

​

Phase 1b/2a of the study explored whether AB-2004’s ability to reduce the availability of certain gut bacteria, such as p-cresol, can improve gastrointestinal symptoms and some related behavioural challenges in autistic individuals.

​

Phase 2b of the study investigated whether treatment with AB-2004 can improve irritability in autistic children. Eligible participants were randomly assigned to receive AB-2004 or a placebo.

​

You can read more on the study's website.